Strategies used for MUC1 immunotherapy: human clinical studies (Q37259597)

19 August 2017

1 reference

title

Strategies used for MUC1 immunotherapy: human clinical studies (English)

1 reference

19 August 2017

1 reference

Vasso Apostolopoulos

3

0 references

author name string

Choon-Kit Tang

series ordinal

1

1 reference

PubMed ID

18767946

19 August 2017

Maria Katsara

series ordinal

2

1 reference

19 August 2017

1 September 2008

1 reference

Expert Review of Vaccines

19 August 2017

1 reference

19 August 2017

7

1 reference

19 August 2017

7

1 reference

19 August 2017

963-975

1 reference

Breast cancer immunotherapy: current status and future prospects

19 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Aspects of cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Identification and expression of human epiglycanin/MUC21: a novel transmembrane mucin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

MUC1 as a target antigen for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

MUC1 immunobiology: from discovery to clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Strategies used for MUC1 immunotherapy: preclinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Expression of aberrantly glycosylated tumor mucin-1 on human DC after transduction with a fiber-modified adenoviral vector.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Transduction with a fiber-modified adenoviral vector is superior to non-viral nucleofection for expressing tumor-associated Ag mucin-1 in human DC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Transduction of human dendritic cells with a recombinant modified vaccinia Ankara virus encoding MUC1 and IL-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Synergistic induction of antigen-specific CTL by fusions of TLR-stimulated dendritic cells and heat-stressed tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Tumor-Associated Tn-MUC1 Glycoform Is Internalized through the Macrophage Galactose-Type C-Type Lectin and Delivered to the HLA Class I and II Compartments in Dendritic Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Design of peptide-based vaccines for cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Receptor-mediated delivery of antigens to dendritic cells: anticancer applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Protein/peptide and DNA vaccine delivery by targeting C-type lectin receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Role of the mannose receptor in the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

MUC1 peptide epitopes associated with five different H-2 class I molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Crystal structure of a non-canonical low-affinity peptide complexed with MHC class I: a new approach for vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Induction of T1 (cytotoxic lymphocyte) and/or T2 (antibody) responses to a mucin-1 tumour antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Oxidised mannan antigen conjugates preferentially stimulate T1 type immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Mannan mucin-1 peptide immunization: influence of cyclophosphamide and the route of injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835].

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Applications of peptide mimetics in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Mimics and cross reactions of relevance to tumour immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Carbohydrate/peptide mimics: effect on MUC1 cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Dendritic cells in vaccination therapies of malignant diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Dendritic cells: activation and maturation--applications for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Cell fusion: from hybridoma to dendritic cell-based vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Dendritic cell-tumor fusion vaccines for renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

L-BLP25: a peptide vaccine strategy in non small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

L-BLP25: a MUC1-targeted peptide vaccine therapy in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Clinical development of MVA-based therapeutic cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

The immune response of mice and cynomolgus monkeys to macaque mucin 1-mannan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Anti-mucin monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Mouse mucin 1 (MUC1) defined by monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken Up by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Mannan derivatives induce phenotypic and functional maturation of mouse dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Enhancing efficacy of therapeutic vaccinations by combination with other modalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Theratope vaccine (STn-KLH).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Vaccination with Theratope (STn-KLH) as treatment for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Methods of Delivery to Antigen-Presenting Cells: Development of New and Improved Vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Cell-mediated immune responses to MUC1 fusion protein coupled to mannan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Cytokine Production from Murine CD4 and CD8 Cells After Mannan-MUC1 Immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Parameters for using mannan-MUC1 fusion protein to induce cellular immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

Peptide mimics of a tumor antigen induce functional cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

MUC1 cross-reactive Galα(l,3)Gal antibodies in humans switch immune responses from cellular to humoral

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.7.963

21 January 2018

Identifiers

DOI

10.1586/14760584.7.7.963

1 reference

19 August 2017

1 reference

PubMed ID

18767946